5th Edition of International Heart Congress
June 24-26, 2027 | Hybrid Event
Cardiovascular Pharmacology and Therapeutics
Cardiovascular pharmacology and therapeutics form the backbone of managing heart-related conditions through targeted drug development and clinical applications. Medications like beta-blockers, ACE inhibitors, and antiplatelet agents play a critical role in treating hypertension, heart failure, and coronary artery disease. Advances in this field have led to novel therapeutics, including sodium-glucose cotransporter-2 (SGLT2) inhibitors and PCSK9 inhibitors, which offer new hope for patients with complex cardiovascular conditions. Ongoing research focuses on personalized medicine, exploring how genetic factors influence drug response to optimize treatment strategies. By blending pharmacology with innovative therapies, this field aims to improve cardiovascular outcomes while minimizing side effects.
John R Doty
Intermountain Medical Center, United States
Trevor Tucker
Dynamic Vascular Resolution Inc., Canada
Thomas J Webster
Brown University, United States
Uwe Peter Tigor
Auxilius Pharma, United States
Fatima Michelle Villa Jimenez
Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas, Mexico
Mancilla Sandoval Yoana Tenneth
Instituto Nacional de Enfermedades Respiratorias "Ismael Cosío Villegas", Mexico
Sergey Suchkov
N. D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian FederationSubmit your abstract Today
Title : Healing a broken heart: One nano beat at a time
Thomas J Webster, Brown University, United States
Title : Surgical options for aortic valve preservation
John R Doty, Intermountain Medical Center, United States
Title : Revolutionizing heart health through Personalized & Precision Medicine (PPM): Towards personalized cardiovascular prevention, precision cardiac care & rehabilitation via optimizing Cardiac Hospital Networks
Sergey Suchkov, N. D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation
Title : Antibody-proteases as unique biomarkers, potential targets and translational tools of the next step generation to be used in personalized and precision cardiology practice
Sergey Suchkov, N. D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation
Title : Investigation of bergapten’s pharmacological activity against doxorubicin induced cardiotoxicity: supporting evidence from cellular and animal models
Bijoy Krishna Banik, National Institute of Pharmaceutical Education and Research (NIPER)-Guwahati, India
Title : Frequency of residual risk in cardiovascular secondary prevention in patients treated at the Reina Fabiola University Clinic
Agustin Joison, Cordoba Catholic University, Argentina